AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth CareGeographicals
Myeloproliferative DisordersJanus Kinase 2Polycythemia VeraPrimary MyelofibrosisThrombocythemia, EssentialMyelodysplastic-Myeloproliferative DiseasesBone Marrow NeoplasmsReceptors, ThrombopoietinThrombocytosisLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeDNA, NeoplasmLeukemia, Myelomonocytic, JuvenileAnemia, RefractoryMutationProto-Oncogene Proteins c-cblMyelodysplastic SyndromesSplenomegalyPhiladelphia ChromosomeHematologic NeoplasmsJanus KinasesMegakaryocyte Progenitor CellsSTAT5 Transcription FactorLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematologyLeukemia, Myeloid, AcuteNeoplasmsClonal EvolutionBone MarrowHematopoietic Stem CellsPancreatic NeoplasmsFusion Proteins, bcr-ablBlast CrisisMutation, MissenseAmino Acid SubstitutionProtein Kinase InhibitorsGene Knock-In TechniquesDNA Mutational AnalysisMyeloid Progenitor CellsMegakaryocyte-Erythroid Progenitor CellsMyelopoiesisAnemia, SideroblasticLeukemia, MyeloidMegakaryocytesCell Transformation, NeoplasticNeoplasms, Cystic, Mucinous, and SerousBone Marrow DiseasesPoint MutationCell ProliferationHematopoiesis, ExtramedullaryProto-Oncogene ProteinsLeukemiaDisease ProgressionExonsPyrazolesSkin NeoplasmsSignal TransductionPrognosisNeoplasms, Multiple PrimaryLeukemia, Neutrophilic, ChronicKidney NeoplasmsThrombosisDNA-Binding ProteinsNeoplasms, Second PrimaryItalyPhenotypeAllelesPolymerase Chain ReactionAdenocarcinoma, MucinousThyroid NeoplasmsGerm-Line MutationDisease Models, AnimalCohort StudiesMice, Inbred C57BLTreatment OutcomeSarcoma Viruses, MurineHypereosinophilic SyndromeRepressor ProteinsCase-Control StudiesLeukocytosisOncogene Proteins, FusionMoloney murine sarcoma virusAntineoplastic AgentsReceptor, Fibroblast Growth Factor, Type 1Mice, TransgenicPolymorphism, Single NucleotideLung NeoplasmsGene FrequencyParotid NeoplasmsNeoplasm ProteinsHaplotypesCell Line, TumorGenes, ablCystadenomaNeoplasms, Connective and Soft TissueNeoplasms, Plasma CellReal-Time Polymerase Chain ReactionAppendiceal NeoplasmsLiver NeoplasmsImmunohistochemistry
Classic myeloproliferative neoplasmsMPNsPolycythemiaNegative Myeloproliferative NeoplasmsMutationJAK2 V617FMutationsMyelodysplastic syndromeEssential thrombocythemiaDisordersPatientsDiagnosisMetastasisClonalHematologic malignanciesApoptosisMethyltransferaseMyeloid cellBone marrowClinicalDiagnosticInhibitorsGeneticProteinsPrimaryHumansPatient'sStudiesDiscoveryConditionsSerumCancerCells
Classic myeloproliferative neoplasms3
  • INTRODUCTION - An overview of the four classic myeloproliferative neoplasms (MPN): polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia will be presented here. (medilib.ir)
  • The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms. (cdc.gov)
  • Mutations in TET2, other epigenetic regulators, and other regulators of cytokine signaling are not specific to the classic myeloproliferative neoplasms (MPNs) but may influence prognosis and play roles in hematopoietic stem cell (HSC) dysregulation and progression to accelerated or blast-phase disease. (oncohemakey.com)
MPNs10
  • Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. (wikipedia.org)
  • In MPNs, the neoplasm (abnormal growth) starts out as benign and can later become malignant. (wikipedia.org)
  • The discovery of JAK2 V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. (pvreporter.com)
  • Myeloproliferative neoplasms (MPNs) are blood conditions caused by genetic mutations in blood stem cells in the bone marrow. (mympnteam.com)
  • Before the World Health Organization changed terminology in 2008 , MPNs were known as myeloproliferative diseases. (mympnteam.com)
  • Signaling mutations (eg, JAK2V617F) and mutations in genes involved in epigenetic regulation (eg, TET2) are the most common cooccurring classes of mutations in myeloproliferative neoplasms (MPNs). (westminster.ac.uk)
  • Development of a Real-Time qPCR Assay for Detection of Common MPL Mutations in Myeloproliferative Neoplasms (MPNS). (cdc.gov)
  • The World Health Organization (WHO) provides diagnostic criteria for BCR-ABL negative MPNs, including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and myeloproliferative neoplasms, unclassifiable (MPN-U) (1). (iranpath.org)
  • The chronic myeloproliferative neoplasms (MPNs) are clonal disorders characterized by overproduction of mature myeloid cells. (oncohemakey.com)
  • The JAK2V617F mutation is particularly common in the classic MPNs, although it is also found in approximately half of patients with the uncommon myelodysplastic (MDS)/MPN, refractory anemia with ringed sideroblasts and marked thrombocytosis, and at lower frequencies in AML, other myeloproliferative, and myelodysplastic disorders. (oncohemakey.com)
Polycythemia6
  • Depending on the nature of the myeloproliferative neoplasm, diagnostic tests may include red cell mass determination (for polycythemia), bone marrow aspirate and trephine biopsy, arterial oxygen saturation and carboxyhaemoglobin level, neutrophil alkaline phosphatase level, vitamin B12 (or B12 binding capacity), serum urate or direct sequencing of the patient's DNA. (wikipedia.org)
  • Polycythemia vera is a myeloproliferative neoplasm characterized by increased production of red blood cells and often other blood cell lines. (cdc.gov)
  • Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by the overproduction of RBCs. (lecturio.com)
  • In 2006, Dave Boule was diagnosed with polycythemia vera, a type of myeloproliferative neoplasm (MPN) that affects blood cell production in the body. (cornell.edu)
  • Dr. Silver, founder and emeritus director of the Weill Cornell Medicine Richard T. Silver MD Myeloproliferative Neoplasms (MPN) Center, is internationally recognized as a pioneer in the field and initiated the development and use of interferons as a treatment for a number of different myeloproliferative neoplasms, including polycythemia vera. (cornell.edu)
  • Splenomegaly can be seen in many cases of myeloproliferative neoplasm-including chronic myelogeneous leukemia, primary myelofibrosis, polycythemia vera and essential thrombocytosis. (cap.org)
Negative Myeloproliferative Neoplasms4
  • JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker. (cdc.gov)
  • Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms. (cdc.gov)
  • Seventy-one patients with BCR-ABL negative myeloproliferative neoplasms were evaluated for JAK2 V617F, CALR type 1, type 2, and MPL by allele-specific PCR and conventional PCR from 2018 to 2019. (iranpath.org)
  • Seventy-one patients with BCR-ABL negative myeloproliferative neoplasms whose information was registered in the molecular pathology department of Shiraz Medical School, the southwest of Iran, were included in this study from 2018 to 2019. (iranpath.org)
Mutation7
  • According to WHO diagnostic criteria published in 2016, myeloproliferative neoplasms are diagnosed as follows: Chronic myeloid leukemia (CML) has a presence of the hallmark Philadelphia Chromosome (BCR-ABL1) mutation. (wikipedia.org)
  • Indeed, the use of sensitive assays increases the detection rate of the JAK2 V617F mutation within myeloproliferative neoplasms. (ox.ac.uk)
  • This mutation is found in approximately 95% of patients with PV, as well as in some patients with other kinds of myeloproliferative neoplasms (MPN). (cdc.gov)
  • And I think what I get very excited about is that we have new targeted therapies, and by that I mean some of my patients to have certain mutations in their cancers or DNA changes in their cancer, have access to newer treatments like a pill, for example, called in a family called PARP inhibitor, that are really especially effective against cancers that have that type of mutation. (powerfulpatients.org)
  • The JAK2V617F mutation is found in most patients with a myeloproliferative neoplasm (MPN). (westminster.ac.uk)
  • This gain-of-function mutation dysregulates cytokine signaling and is associated with increased accumulation of DNA damage, a process likely to drive disease evolution. (westminster.ac.uk)
  • In addition, DNA studies showed that the patient carried MPL W515L mutation and was negative for JAK2 V617F mutation. (cap.org)
JAK2 V617F1
  • Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. (ox.ac.uk)
Mutations8
  • T) and other pathogenetic mutations within JAK2 exon 12 and MPL exon 10 are part of the routine diagnostic workup for patients presenting with erythrocytosis, thrombocytosis or otherwise suspected to have a myeloproliferative neoplasm. (ox.ac.uk)
  • Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations. (cdc.gov)
  • Analysis of DNA Methylation Gene Mutations and Clinical Features in Patients with Myeloproliferative Neoplasm]. (cdc.gov)
  • This study was conducted to evaluate the frequency of JAK2, CALR and MPL mutations in with BCR-ABL myeloproliferative neoplasms and their association with demographic data and hematologic parameters in a referral center, in the Middle East. (iranpath.org)
  • Due to the different frequency of JAK2, MPL, CALR mutations and the difference in the course of myeloproliferative neoplasms with different mutations and considering that a comprehensive study has not been established in the Iranian population about myeloproliferative neoplasms and these mutations so far, this study was conducted in a referral center in the southwest of Iran, the Middle East. (iranpath.org)
  • Recurrent, somatic, heterozygous mutations in DNMT3A have been reported in approximately 18-25% of cases of acute myeloid leukemia (up to 34% of normal karyotype AML), 12-18% of cases of myelodysplastic syndrome, up to 15% of myeloproliferative neoplasms, less than 5% of cases of chronic myelomonocytic leukemia and 15% of cases of adult, eary T cell precursor acute lymphoblastic leukemia. (cornell.edu)
  • DNMT3A mutations have been associated with reduced enzymatic activity or altered histone binding, as well as reduced DNA methylation in various genomic regions and altered gene expression in some models. (cornell.edu)
  • Rarely, changes in single DNA building blocks (point mutations) in the PDGFRA gene are found in people with this condition. (medlineplus.gov)
Myelodysplastic syndrome1
  • Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes-disorders that include features of both myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN)-are entities whose diagnosis and management have proved challenging. (medscape.com)
Essential thrombocythemia2
  • Studies using refined methods of X-linked DNA analysis have demonstrated polyclonal hematopoiesis in some patients with essential thrombocythemia and monoclonal hematopoiesis in healthy elderly women [ 11 ]. (medilib.ir)
  • Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia. (cdc.gov)
Disorders1
  • Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include disorders that manifest both dysplastic and proliferative features. (medilib.ir)
Patients5
  • Patients with otherwise unexplained thrombosis and with neoplasms that cannot be classified in one of the other categories. (wikipedia.org)
  • Patients' demographic data (like age and sex) and hematologic characteristics of myeloproliferative neoplasms (like hemoglobin level, leukocytosis, and platelet count) were extracted from the database registered in the department of molecular pathology. (iranpath.org)
  • Myeloproliferative neoplasm (MPN) patients can take advantage of a medical advancement called next-generation sequencing. (powerfulpatients.org)
  • The only approved disease-modifying therapies for any of the MDS/MPN are DNA methyltransferase inhibitors (DNMTi) for patients with dysplastic CMML, and still, outcomes are generally poor, making this an important area of unmet clinical need. (elsevierpure.com)
  • The Weill Cornell Medicine Richard T. Silver MD Myeloproliferative Neoplasms (MPN) Center provides specialized, cutting-edge care for patients with a variety of myeloproliferative neoplasms. (cornell.edu)
Diagnosis2
  • The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis. (cdc.gov)
  • He carries a diagnosis of a myeloproliferative neoplasm, for the past 2 years and has progressively become pancytopenic. (cap.org)
Metastasis1
Clonal1
Hematologic malignancies1
  • Background: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and propensity of acute leukemic transformation, and have significant impact on patient quality of life. (elsevierpure.com)
Apoptosis1
  • JAK2V617F inhibits NHE-1 upregulation in response to DNA damage and consequently represses Bcl-xL deamidation and apoptosis, thus giving rise to inappropriate cell survival. (westminster.ac.uk)
Methyltransferase2
  • Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet. (mycancergenome.org)
  • DNMT3A is a DNA methyltransferase. (cornell.edu)
Myeloid cell1
  • Myeloproliferative neoplasms (MPN), unlike MDS, usually exhibit terminal myeloid cell expansion in the peripheral blood [ 7 ]. (medilib.ir)
Bone marrow2
  • Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled. (wikipedia.org)
  • Myeloproliferative neoplasms are a type of blood cancer that occurs when the bone marrow overproduces blood stem cells. (nebula.org)
Clinical1
  • ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. (mycancergenome.org)
Diagnostic1
  • Although disease-defining abnormalities have not yet been found, the present knowledge of these aberrations offers better understanding of these neoplasms and can supplement the morphologic and immunophenotypic diagnostic features. (medscape.com)
Inhibitors1
  • Trials of these inhibitors are in progress for the treatment of the other myeloproliferative neoplasms. (wikipedia.org)
Genetic1
  • Overall, these variants may explain over 18% of the total genetic risk for developing myeloproliferative neoplasms. (nebula.org)
Proteins2
  • [ 2 ] Histones are proteins that both provide structural support for DNA (DNA wraps around a core of histones to form nucleosomes) and are involved in the regulation of gene expression. (medscape.com)
  • Bioactivation of pyrrolizidine alkaloids by the P450 enzyme system produces highly reactive toxic metabolites, which can bind to proteins or DNA, forming adducts. (usda.gov)
Primary2
Humans1
Patient's1
  • Next-generation sequencing is a DNA analysis process that allows for sequencing of a portion of a patient's genome. (powerfulpatients.org)
Studies1
  • Similar to previous studies the most common neoplasm present in all treatment groups was hemangiosarcoma. (usda.gov)
Discovery1
  • Discovery of 17 regions of the genome associated with a risk of myeloproliferative neoplasms, a type of blood cancer. (nebula.org)
Conditions1
  • Interferons have been developed as drugs to treat a number of conditions, including myeloproliferative neoplasms. (cornell.edu)
Serum1
  • Neoplasms containing cyst-like formations or producing mucin or serum. (lookformedical.com)
Cancer1
  • So can't we learn about this whether it's a good fit or whether that person's cancer might especially be well treated by that drug by doing DNA sequencing of the cancer or DNA sequencing of that person's DNA, inherited DNA. (powerfulpatients.org)
Cells4
  • There are multiple types of myeloproliferative neoplasms, which are categorized by the cells affected. (nebula.org)
  • Hydrea interferes with DNA, preventing cells from dividing. (mympnteam.com)
  • In this study, we demonstrate that the accumulation of reactive oxygen species (ROS) in cells expressing JAK2V617F compromises the NHE-1/Bcl-xL deamidation pathway by repressing NHE-1 upregulation in response to DNA damage. (westminster.ac.uk)
  • It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. (lookformedical.com)